** Cancer therapy maker Novocure's NVCR.O shares up 4.3% at $16.25
** NVCR says its cancer therapy, Optune Lua, to treat a type of lung cancer, has received a CE (Conformité Européenne) mark in Europe
** The CE marking certifies that a product has met EU health, safety, and environmental requirements
** CE mark approval is based on late-stage study results that showed the therapy, which uses electric fields to kill cancer cells while sparing most nearby healthy cells, also improved survival rates of patients over 8 years - NVCR
** CE mark comes after FDA's approval of Optune Lua in October 2024
** As of last close, NVCR had fallen 45.% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。